Drug Trial Radar · NCT07345390
Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jan 10, 2026
Primary completion
Oct 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, efficacy and pharmacokinetics of KR230109 cream compared with placebo in Patients (18-40 Years) with Acne vulgaris
Conditions
- Acne Vulgaris
Interventions
KR230109 cream 0.025%Drug
KR230109 cream 0.025% is indicated for the topical treatment of acne vulgaris in patients
KR230109 cream 0.05%Drug
KR230109 cream 0.05% is indicated for the topical treatment of acne vulgaris in patients
PlaceboDrug
Vehicle cream manufactured to mimic look and feel of KR230109 Cream but without the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage change from baseline in the count of non-inflammatory facial lesionsTime frame: week 12
- The percentage change from baseline in the count of inflammatory facial lesionsTime frame: week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.